Fenretinide (Synonyms: 4-HPR; フェンレチニド)

Name: Fenretinide
Brand: MedChemExpress
SKU: HY-15373
Rating: 5.0 (9 reviews)

製品番号: HY-15373 純度: 98.34%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Fenretinide (4-HPR) is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 65646-68-6

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 46	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 46	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$42	在庫あり	Estimated Time of Arrival: December 31
10 mg	$66	在庫あり	Estimated Time of Arrival: December 31
25 mg	$92	在庫あり	Estimated Time of Arrival: December 31
50 mg	$118	在庫あり	Estimated Time of Arrival: December 31
100 mg	$158	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 9 publication(s) in Google Scholar

Other Forms of Fenretinide:

Fenretinide (Standard) お問い合わせ

顧客検証

IHC

: Fenretinide purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Jul;40(1):518-526. [Abstract]; Western blot analyses reveal that the phosphorylation of p38 is significantly increased. Lane 1, cell control; lane 2, DMSO; lane 3, 5 μM ATRA; lane 4, 10 μM ATRA; lane 5, 5 μM 4-HPR; and lane 6, 10 μM 4-HPR.

: Fenretinide purchased from MedChemExpress. Usage Cited in: Cornea. 2018 Dec;37(12):1579-1585. [Abstract]; Fenretinide pretreatment reduces neutrophils recruitment and MPO activity in the mouse Aspergillus fumigatus keratitis model. Positive staining (green) of NIMP-R14 in the corneas of pretreated mice is indicative of a decreased presence of neutrophils compared with control mice at 1 day after infection.

: Fenretinide purchased from MedChemExpress. Usage Cited in: Cornea. 2018 Dec;37(12):1579-1585. [Abstract]; Compared with infected controls, LOX-1, phosphorylated JNK, and pro-IL-1b protein levels in corneas are significantly lower at 1 day after infection in fenretinide-pretreated mice.

: Fenretinide purchased from MedChemExpress. Usage Cited in: Cornea. 2018 Dec;37(12):1579-1585. [Abstract]; Compared with stimulated controls, LOX-1, JNK, phosphorylated JNK, and pro-IL-1b protein levels in fenretinide-pretreated THP-1 macrophages are significantly lower at 16 hours with A. fumigatus stimulation. JNK was not affected by fenretinide pretreatment.

: Fenretinide purchased from MedChemExpress. Usage Cited in: Cornea. 2018 Dec;37(12):1579-1585. [Abstract]; BAX, cytochrome c, cleaved-caspase-8, cleaved-caspase-9, and cleaved-caspase-3 protein levels in fenretinide-pretreated mice corneas are found to be significantly increased.

RAR/RXR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

RXRα RXRβ RXRγ

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Fenretinide (4-HPR) is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.

Cellular Effect

Cell Line	Type	Value	Description	References
Astrocyte	EC₅₀	2.399 μM Compound: 11	Antiproliferative activity against mouse astrocyte cells by MTT assay Antiproliferative activity against mouse astrocyte cells by MTT assay	[PMID: 17417631]
BHK-21	CC₅₀	31.5 μM Compound: 192	Cytotoxicity against BHK21 cells in presence of ATP by Celltiter-Glo assay Cytotoxicity against BHK21 cells in presence of ATP by Celltiter-Glo assay	[PMID: 28689975]
CWR22R	GI₅₀	3.23 μM Compound: 4-HPR, fenretinide	Growth inhibition of human CWR22Rv1 cells by MTT assay Growth inhibition of human CWR22Rv1 cells by MTT assay	[PMID: 25634130]
Daoy	GI₅₀	5 μM Compound: Fenretinide	Antiproliferative activity against human Daoy cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay Antiproliferative activity against human Daoy cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay	[PMID: 33636537]
G-401	IC₅₀	5 μM Compound: 1	Cytotoxicity against human G401 cells assessed as cell survival after 3 days by MTS assay Cytotoxicity against human G401 cells assessed as cell survival after 3 days by MTS assay	[PMID: 18556204]
HEK-293T	IC₅₀	18.7 μM Compound: Fenretinide	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HEK-293T	IC₅₀	59.9 μM Compound: Fenretinide	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HuCCT-1	IC₅₀	6 μM Compound: 3, Fenretinide	Cytotoxicity against human HuCCT1 cells after 72 hrs by MTT assay Cytotoxicity against human HuCCT1 cells after 72 hrs by MTT assay	[PMID: 22440084]
Huh-7	CC₅₀	<= 10 μM Compound: 4-HPR	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay	[PMID: 37159959]
LNCaP	GI₅₀	2.69 μM Compound: 4-HPR, fenretinide	Growth inhibition of human LNCAP cells by MTT assay Growth inhibition of human LNCAP cells by MTT assay	[PMID: 25634130]
LNCaP	IC₅₀	7.5 μM Compound: 4-HPR	Growth inhibition of human LNCaP cells after 6 days by MTT assay Growth inhibition of human LNCaP cells after 6 days by MTT assay	[PMID: 15615521]
MCF7	GI₅₀	4.65 μM Compound: 4-HPR, fenretinide	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 25634130]
MCF7	IC₅₀	0.15 μM Compound: 4-HPR	Growth inhibition of human MCF7 cells after 6 days by MTT assay Growth inhibition of human MCF7 cells after 6 days by MTT assay	[PMID: 15615521]
MDA-MB-231	GI₅₀	11.05 μM Compound: 4-HPR, fenretinide	Growth inhibition of human MDA-MB-231 cells by MTT assay Growth inhibition of human MDA-MB-231 cells by MTT assay	[PMID: 25634130]
MDA-MB-231	IC₅₀	7.7 μM Compound: 4-HPR	Growth inhibition of human MDA-MB-231 cells after 6 days by MTT assay Growth inhibition of human MDA-MB-231 cells after 6 days by MTT assay	[PMID: 15615521]
MDA-MB-468	GI₅₀	6.02 μM Compound: 4-HPR, fenretinide	Growth inhibition of human MDA-MB-468 cells by MTT assay Growth inhibition of human MDA-MB-468 cells by MTT assay	[PMID: 25634130]
MIA PaCa-2	IC₅₀	7 μM Compound: 3, Fenretinide	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 22440084]
Medulloblastoma cell	EC₅₀	0.204 μM Compound: 11	Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay	[PMID: 17417631]
ONS-76	GI₅₀	2 μM Compound: Fenretinide	Antiproliferative activity against human ONS-76 cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay Antiproliferative activity against human ONS-76 cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay	[PMID: 33636537]
PC-3	GI₅₀	2 μM Compound: 43	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26780304]
PC-3	GI₅₀	3.54 μM Compound: 4-HPR, fenretinide	Growth inhibition of human PC3 cells by MTT assay Growth inhibition of human PC3 cells by MTT assay	[PMID: 25634130]
PC-3	IC₅₀	3.6 μM Compound: 4-HPR	Growth inhibition of human PC3 cells after 6 days by MTT assay Growth inhibition of human PC3 cells after 6 days by MTT assay	[PMID: 15615521]
SK-BR-3	GI₅₀	3.98 μM Compound: 4-HPR, fenretinide	Growth inhibition of human SKBR3 cells by MTT assay Growth inhibition of human SKBR3 cells by MTT assay	[PMID: 25634130]

体外実験

Fenretinide (4-HPR) exerts not just acute but also long term antitumor activity in selected T-ALL cell lines. Fenretinide inhibits DES activity in CCRF-CEM leukemia cells in a dose and time dependent manner, leading to a concomitant increase of the endogenous cellular dhCer content. Fenretinide (3 μM)-induced dhCer accumulation in both CCRF-CEM and Jurkat cells^[1]. Ceramide inhibition with fenretinide protects insulin signaling. Fenretinide prevents lipid-induced reductions in insulin-stimulated glucose uptake^[2]. Fenretinide inhibits OVCAR-5 cell proliferation and viability at concentrations higher than 1 microM, with 70-90% growth inhibition at 10 microM. Fenretinide (1 microM) significantly inhibits OVCAR-5 invasion after 3 days preincubation. Endothelial cells treated with 1 microM 4-HPR fails to form tubes, but forms small cellular aggregates^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Fenretinide (4-HPR) (10 mg/kg, i.p.) selectively inhibits ceramide accumulation HFD-fed male C57Bl/6 mice. Fenretinide treatment improves glucose tolerance and insulin sensitivity as determined by both glucose and insulin tolerance tests^[2]. Addition of 25 mg/kg ketoconazole to Fenretinide in NOD/SCID mice increased 4-HPR plasma levels^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

391.55

分子式

C₂₆H₃₃NO₂

CAS 番号

65646-68-6

Appearance

Solid

Color

Light yellow to yellow

SMILES

CC(/C=C/C=C(/C=C/C1=C(CCCC(C)1C)C)C)=C\C(NC2=CC=C(O)C=C2)=O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (255.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5540 mL	12.7698 mL	25.5395 mL
5 mM	0.5108 mL	2.5540 mL	5.1079 mL
10 mM	0.2554 mL	1.2770 mL	2.5540 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 98.34%

Select Batch:

データシート (276 KB) SDS (419 KB)

COA (241 KB) LCMS (99 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Apraiz, Aintzane., et al. Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochemistry and Cell Biology (2012), 90(2), 209-223. [Content Brief]

[2]. Bikman, Benjamin T., et al. Fenretinide Prevents Lipid-induced Insulin Resistance by Blocking Ceramide Biosynthesis. Journal of Biological Chemistry (2012), 287(21), 17426-17437. [Content Brief]

[3]. Cooper JP, et al. Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol. 2011 Jul;163(6):1263-75. [Content Brief]

[4]. Golubkov V, et al. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res. 2005 Jan-Feb;25(1A):249-53. [Content Brief]

細胞実験 ^[1]	Standard XTT assay is used to determine cell viability. For fenretinide-only treatments, cells are plated in 96-well plates at 750,000 cells/mL and 100 μL/well. After 4 h, treatments are added on 50 μL/well obtaining a final density of 500,000 cells/mL and final volume of 150 μL/well. Four replicates are used per experimental condition. XTT reagent mixture is added 4 h before the end of selected treatment period and absorbance at 490 nm is determined per each well. A slightly modified protocol is used for analysis of the effect of myriocin (final concentration of 100 nM) or antioxidant on Fenretinide treatment. Briefly, cells are seeded on 60 mm culture dishes and myriocin or antioxidants added after 4 h. Fenretinide treatment is added 2 h later and cells are plated in quadruplicates in 96 well plates (150 μL/well). MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[2]	Male mice (C57Bl6) are fed a standard chow or a high-fat diet (HFD) from 5 to 17 weeks, at which point half of the HFD-fed mice begin receiving fenretinide in drinking water for 4 weeks. Fenretinide is dissolved in 100% ethanol and diluted in water to 10 μg/mL. Control treatment water receives an equal amount of ethanol (0.5%). FEN water is prepared in low-light conditions and administered in light-protective bottles. Water is replaced every 1-2 days, and no precipitation of FEN is noted at any time. Animal weights are recorded at the beginning and end of the treatment period. Following a 4-week FEN treatment, mice undergo intraperitoneal glucose and insulin tolerance tests. For both tests, mice are fasted for 6 h andreceive an injection of either glucose (1 g/kg of body weight) or insulin (0.75 units/kg of body weight). Blood glucose is determined at the times indicated by the Bayer Contour^® glucose meter, and insulin is measured with the rat/mouse insulin ELISA kit. The insulin resistance index is assessed by using fasting blood glucose and insulin levels to compute the homeostatic model assessment of insulin resistance (HOMA-IR), where a higher number represents greater insulin resistance. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Apraiz, Aintzane., et al. Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochemistry and Cell Biology (2012), 90(2), 209-223. [Content Brief] [2]. Bikman, Benjamin T., et al. Fenretinide Prevents Lipid-induced Insulin Resistance by Blocking Ceramide Biosynthesis. Journal of Biological Chemistry (2012), 287(21), 17426-17437. [Content Brief] [3]. Cooper JP, et al. Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol. 2011 Jul;163(6):1263-75. [Content Brief] [4]. Golubkov V, et al. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res. 2005 Jan-Feb;25(1A):249-53. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5540 mL	12.7698 mL	25.5395 mL	63.8488 mL
	5 mM	0.5108 mL	2.5540 mL	5.1079 mL	12.7698 mL
	10 mM	0.2554 mL	1.2770 mL	2.5540 mL	6.3849 mL
	15 mM	0.1703 mL	0.8513 mL	1.7026 mL	4.2566 mL
	20 mM	0.1277 mL	0.6385 mL	1.2770 mL	3.1924 mL
	25 mM	0.1022 mL	0.5108 mL	1.0216 mL	2.5540 mL
	30 mM	0.0851 mL	0.4257 mL	0.8513 mL	2.1283 mL
	40 mM	0.0638 mL	0.3192 mL	0.6385 mL	1.5962 mL
	50 mM	0.0511 mL	0.2554 mL	0.5108 mL	1.2770 mL
	60 mM	0.0426 mL	0.2128 mL	0.4257 mL	1.0641 mL
	80 mM	0.0319 mL	0.1596 mL	0.3192 mL	0.7981 mL
	100 mM	0.0255 mL	0.1277 mL	0.2554 mL	0.6385 mL

Fenretinide Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fenretinide65646-68-64-HPR ISLA-101ISLA101ISLA 101ISLA-101RAR/RXRAutophagyRetinoic acid receptorsRetinoid X receptorsInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Fenretinide (Synonyms: 4-HPR; フェンレチニド)

カスタマーレビュー

Other Forms of Fenretinide:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

RAR/RXR アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fenretinide Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Fenretinide (Synonyms: 4-HPR; フェンレチニド)

カスタマーレビュー

Other Forms of Fenretinide:

Fenretinide 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

RAR/RXR アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Fenretinide 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fenretinide Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report